 Factor Xa Inhibitors
"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
| Descriptor ID |
D065427
|
| MeSH Number(s) |
D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".
This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 3 | 4 | 7 | | 2014 | 1 | 5 | 6 | | 2015 | 2 | 4 | 6 | | 2016 | 5 | 4 | 9 | | 2017 | 5 | 3 | 8 | | 2018 | 5 | 5 | 10 | | 2019 | 8 | 3 | 11 | | 2020 | 10 | 5 | 15 | | 2021 | 7 | 8 | 15 | | 2022 | 1 | 3 | 4 | | 2023 | 0 | 3 | 3 | | 2024 | 4 | 2 | 6 | | 2025 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.
-
Weitz JI, Kithcart AP, O'Brien MP, Levy O, Marin E, Onisko M, Mohammadi KA, Li D, Meagher KA, Chang HH, Olenchock BA, Gutstein DE, Segers A, Roberts RS, Bonaca MP, Raskob GE. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials. Lancet. 2025 Nov 29; 406(10519):2551-2563.
-
Hogan S, Szarek M, Debus ES, Nehler M, Anand SS, Patel MR, Pap AF, Deng H, Hodge S, Haskell LP, Muehlhofer E, Berkowitz SE, Bauersachs RM, Bonaca MP. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. J Am Heart Assoc. 2025 Nov 04; 14(21):e039752.
-
Verheye S, Ferdinande B, Bennett J, Staico R, El-Jack S, Tonino PAL, Abizaid A, Buysschaert I, Scott D, Menon M, Wilkins G, McClean D, Kovarnik T, Christians U, Neylon A, Mehmedbegovic Z, Smits PC, Morice MC, Webster M. Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus. Catheter Cardiovasc Interv. 2025 Oct; 106(4):2770-2780.
-
Kurth LM, Marshall WA, Stone LE, Hirshman BR, Box K, Haines LN, Smith AM, Costantini TW, Berndtson AE. It's all in your head: Safety of weight-based, targeted enoxaparin prophylaxis in intracranial hemorrhage patients. Surgery. 2025 Aug; 184:109476.
-
Hanke P, Domingo ME, Salanio G, Ahmed K, Hu J, Hendricks K, Howard J, Hashimura T, Guiliano C, Haan BJ, Ng TH, Kelley D, Knight T, Koopman K, Obstoj M, Breeden T, Sirbu D, Romano M, Harpenau A, Konneker R, Acevedo J, Pan N, Edwin SB. Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study. J Thromb Thrombolysis. 2025 Mar; 58(3):380-390.
-
Blotske K, Patel T, Trujillo T, Marlar M, Lind S, Kramer H, Hassell K, Kiser TH. Evaluation of Rivaroxaban Exposure via Anti-Xa Levels During VTE Prophylaxis in Hospitalized Patients. Clin Appl Thromb Hemost. 2025 Jan-Dec; 31:10760296251319961.
-
Canonico ME, Low Wang CC, Hsia J, Debus ES, Nehler MR, Patel MR, Anand SS, Ycas J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs R, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization. J Am Coll Cardiol. 2024 Aug 27; 84(9):801-811.
-
Harrington J, Hellkamp AS, Mahaffey KW, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Fox KAA, Singer DE, Goodman SG, Patel MR, Piccini JP. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. J Am Heart Assoc. 2024 Jun 04; 13(11):e028951.
-
Floyd J, Porragas-Paseiro H, Nguyen C, Moroney MR, Mastroyannis S, Guntupalli SR. Validation of the Safety and Efficacy of Apixaban as Postoperative Thromboembolism Prophylaxis for Patients with Gynecologic Malignancies. Ann Surg Oncol. 2024 Aug; 31(8):5102-5110.
-
Morrison JT, Canonico ME, Anand SS, Patel MR, Debus ES, Nehler MR, Hess CN, Hsia J, Capell WH, Muehlhofer E, Haskell LP, Berkowitz SD, Bauersachs RM, Bonaca MP. Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation. 2024 May 07; 149(19):1536-1539.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|